111 Capital Makes New $1.39 Million Investment in Stryker Corporation $SYK

111 Capital bought a new stake in Stryker Corporation (NYSE:SYK) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,763 shares of the medical technology company’s stock, valued at approximately $1,391,000.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Stryker by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock worth $12,485,012,000 after acquiring an additional 272,828 shares during the last quarter. State Street Corp lifted its position in shares of Stryker by 1.0% during the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock valued at $5,929,765,000 after purchasing an additional 150,204 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Stryker by 1.1% during the second quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock worth $2,910,445,000 after purchasing an additional 79,654 shares during the last quarter. Alliancebernstein L.P. grew its position in Stryker by 307.6% in the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after purchasing an additional 4,223,366 shares in the last quarter. Finally, Norges Bank purchased a new stake in Stryker in the 2nd quarter valued at about $1,882,173,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Barclays reaffirmed an “overweight” rating and issued a $469.00 target price on shares of Stryker in a report on Monday, February 2nd. Citizens Jmp raised Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price objective on the stock in a research report on Friday, December 19th. Sanford C. Bernstein raised their target price on Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Wells Fargo & Company increased their price target on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Thirteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $426.47.

Stryker Price Performance

Shares of NYSE:SYK opened at $387.34 on Monday. The firm has a market capitalization of $148.23 billion, a PE ratio of 46.11, a P/E/G ratio of 2.26 and a beta of 0.85. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $363.17 and a two-hundred day moving average price of $369.09. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same period in the prior year, the company posted $4.01 EPS. Stryker’s revenue was up 11.4% compared to the same quarter last year. Equities analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is 41.90%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.